Table 3.
In vitro antifungal susceptibilities (μg/mL) of 98 isolates collected from the 18-month survey, using Clinical and Laboratory Standards Institute (CLSI) methods
| Drug | C. albicans (n = 37) | C. parapsilosis (n = 34) | C. glabrata (n = 9) | C. tropicalis (n = 9) | C. guilliermondii (n = 1) | C. intermedia (n = 1) | C. norvegensis (n = 1) | A. fumigatus (n = 5) | S. apiospermum (n = 1) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Range | MIC90 | Range | MIC90 | Range | MIC90 | Range | MIC90 | MIC | MIC | MIC | Range | MIC | |
| AmB | 0.25–1 | 1 | 0.12–2 | 1 | 0.5–1 | 0.5 | 0.5–2 | 2 | 0.25 | 1 | 0.5 | 0.25–0.5 | >16 |
| AND | 0.008 –2 | 0.25 | 0.03–2 | 2 | 0.008–1 | 0.5 | 0.06–0.5 | 0.25 | 1 | 0.5 | 0.06 | 0.03 | >16 |
| CSP | 0.03–4 | 0.25 | 0.25–8 | 2 | 0.008–4 | 0.5 | 0.25–2 | 0.12 | 4 | 1 | 1 | 0.008 –0.06 | >16 |
| FLC | 0.06–4 | 0.5 | 0.06–8 | 4 | 4–128 | 128 | 0.5–128 | 128 | 4 | 2 | 0.5 | – | – |
| PSC | 0.016–0.25 | 0.12 | 0.03–0.5 | 0.25 | 0.25–16 | 16 | 0.12–8 | 0.5 | 0.25 | 0.03 | 0.016 | 0.06–0.12 | 0.5 |
| VRC | 0.008–0.25 | 0.016 | 0.008–2 | 0.5 | 0.06–4 | 4 | 0.03–16 | 16 | 0.06 | 0.016 | 0.008 | 0.06–0.25 | 0.25 |
AmB amphotericin B, AND anidulafungin, CSP caspofungin, FLC fluconazole, PSC posaconazole, VRC voriconazole